FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3127770250> ?p ?o ?g. }

• W3127770250 endingPage "977" @default.
• W3127770250 startingPage "967" @default.
• W3127770250 abstract "The liver is the most frequent site for metastatic spread in colorectal cancer (CRC) patients, and these patients have much poorer prognosis than those without metastasis. Previous studies have shown that IgG Fc binding protein (FCGBP) plays important roles in tumorigenesis, progression, and prognosis, but its role in CRC metastasis remains unclear.In this study, we are aimed to explore the significance of FCGBP in liver metastatic CRC (LMCRC) patients.We analyzed the expression of FCGBP RNA between CRC primary samples and liver metastatic samples in the Gene Expression Omnibus (GEO) database and The Cancer Genome Atlas (TCGA). Next, we assessed the expression of FCGBP protein in 135 paired primary CRC (PC) samples and LMCRC samples. Finally, we explored the relationship between the expression features and clinicopathological characteristics.The expression data of FCGBP were obtained from the GEO and TCGA databases. FCGBP RNA expression was evaluated between primary lesions (PC) and liver metastatic lesions (LM). FCGBP RNA was down-regulated in PC and LM, and especially lower in LM (p<0.001). Next, the expression of FCGBP protein was evaluated by an immunohistochemistry array in 135 paired primary tumor tissues and metastatic tissues. We found that FCGBP protein was down-regulated in primary lesions and metastatic lesions, especially in metastatic lesions. According to the immunohistochemistry score (SI), each cohort was divided into FCGBP-positive (SI=4-12) and FCGBP-negative (SI=0-3) groups. In both groups, the levels of CEA (PC group, 3.880 vs 77.049, p<0.001; LM group, 3.890 vs 14.239, p=0.008) and CA19-9 (PC group, 8.610 vs 111.700, p<0.001; LM group, 7.660 vs 19.380, p=0.037) were lower than those in the FCGBP-negative group. FCGBP positivity in the LM cohort was an independent risk factor in both overall survival (HR 1.573, 95% Cl [1.017-2.433], p=0.042) and disease-free survival (HR 1.869, 95% Cl [1.256-2.781], p=0.002).This study found a relationship between FCGBP expression and clinical information of LMCRC patients, and found that FCGBP expression decreased with disease development. The expression of FCGBP in liver metastasis is associated with both the overall and progression-free survival. Our results show that FCGBP could be a promising prognostic factor for LMCRC." @default.
• W3127770250 created "2021-02-15" @default.
• W3127770250 creator A5002717172 @default.
• W3127770250 creator A5015643825 @default.
• W3127770250 creator A5021543751 @default.
• W3127770250 creator A5025454498 @default.
• W3127770250 creator A5032550098 @default.
• W3127770250 creator A5040361329 @default.
• W3127770250 creator A5074242312 @default.
• W3127770250 creator A5078281605 @default.
• W3127770250 creator A5083425767 @default.
• W3127770250 creator A5085115089 @default.
• W3127770250 creator A5086762567 @default.
• W3127770250 date "2021-02-01" @default.
• W3127770250 modified "2023-10-14" @default.
• W3127770250 title "IgG Fc Binding Protein (FCGBP) is Down-Regulated in Metastatic Lesions and Predicts Survival in Metastatic Colorectal Cancer Patients" @default.
• W3127770250 cites W1496827497 @default.
• W3127770250 cites W1976584386 @default.
• W3127770250 cites W1979522770 @default.
• W3127770250 cites W1981538589 @default.
• W3127770250 cites W1993153599 @default.
• W3127770250 cites W2001195368 @default.
• W3127770250 cites W2039727733 @default.
• W3127770250 cites W2057589746 @default.
• W3127770250 cites W2127396827 @default.
• W3127770250 cites W2128782671 @default.
• W3127770250 cites W2129458135 @default.
• W3127770250 cites W2149277033 @default.
• W3127770250 cites W2158318418 @default.
• W3127770250 cites W2173279126 @default.
• W3127770250 cites W2272984102 @default.
• W3127770250 cites W2302003756 @default.
• W3127770250 cites W2461369766 @default.
• W3127770250 cites W2756989878 @default.
• W3127770250 cites W2905064718 @default.
• W3127770250 cites W2910301764 @default.
• W3127770250 cites W2955163787 @default.
• W3127770250 cites W3006260860 @default.
• W3127770250 cites W3026738044 @default.
• W3127770250 doi "https://doi.org/10.2147/ott.s285171" @default.
• W3127770250 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7886382" @default.
• W3127770250 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33603401" @default.
• W3127770250 hasPublicationYear "2021" @default.
• W3127770250 type Work @default.
• W3127770250 sameAs 3127770250 @default.
• W3127770250 citedByCount "18" @default.
• W3127770250 countsByYear W31277702502021 @default.
• W3127770250 countsByYear W31277702502022 @default.
• W3127770250 countsByYear W31277702502023 @default.
• W3127770250 crossrefType "journal-article" @default.
• W3127770250 hasAuthorship W3127770250A5002717172 @default.
• W3127770250 hasAuthorship W3127770250A5015643825 @default.
• W3127770250 hasAuthorship W3127770250A5021543751 @default.
• W3127770250 hasAuthorship W3127770250A5025454498 @default.
• W3127770250 hasAuthorship W3127770250A5032550098 @default.
• W3127770250 hasAuthorship W3127770250A5040361329 @default.
• W3127770250 hasAuthorship W3127770250A5074242312 @default.
• W3127770250 hasAuthorship W3127770250A5078281605 @default.
• W3127770250 hasAuthorship W3127770250A5083425767 @default.
• W3127770250 hasAuthorship W3127770250A5085115089 @default.
• W3127770250 hasAuthorship W3127770250A5086762567 @default.
• W3127770250 hasBestOaLocation W31277702501 @default.
• W3127770250 hasConcept C121608353 @default.
• W3127770250 hasConcept C126322002 @default.
• W3127770250 hasConcept C142724271 @default.
• W3127770250 hasConcept C143998085 @default.
• W3127770250 hasConcept C204232928 @default.
• W3127770250 hasConcept C2779013556 @default.
• W3127770250 hasConcept C502942594 @default.
• W3127770250 hasConcept C526805850 @default.
• W3127770250 hasConcept C555283112 @default.
• W3127770250 hasConcept C71924100 @default.
• W3127770250 hasConceptScore W3127770250C121608353 @default.
• W3127770250 hasConceptScore W3127770250C126322002 @default.
• W3127770250 hasConceptScore W3127770250C142724271 @default.
• W3127770250 hasConceptScore W3127770250C143998085 @default.
• W3127770250 hasConceptScore W3127770250C204232928 @default.
• W3127770250 hasConceptScore W3127770250C2779013556 @default.
• W3127770250 hasConceptScore W3127770250C502942594 @default.
• W3127770250 hasConceptScore W3127770250C526805850 @default.
• W3127770250 hasConceptScore W3127770250C555283112 @default.
• W3127770250 hasConceptScore W3127770250C71924100 @default.
• W3127770250 hasLocation W31277702501 @default.
• W3127770250 hasLocation W31277702502 @default.
• W3127770250 hasLocation W31277702503 @default.
• W3127770250 hasLocation W31277702504 @default.
• W3127770250 hasOpenAccess W3127770250 @default.
• W3127770250 hasPrimaryLocation W31277702501 @default.
• W3127770250 hasRelatedWork W2034169702 @default.
• W3127770250 hasRelatedWork W2101676003 @default.
• W3127770250 hasRelatedWork W2355920994 @default.
• W3127770250 hasRelatedWork W2376996112 @default.
• W3127770250 hasRelatedWork W2399421402 @default.
• W3127770250 hasRelatedWork W2773349476 @default.
• W3127770250 hasRelatedWork W2782824587 @default.
• W3127770250 hasRelatedWork W2999877485 @default.
• W3127770250 hasRelatedWork W3032784534 @default.
• W3127770250 hasRelatedWork W4200568016 @default.

• next